P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas. (Q38395549)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

title

P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Massimo Guerriero

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Giuseppe S Bogina

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Gianluigi Lunardi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Lisa Marcolini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Matteo Brunelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Laura Bortesi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Marcella Marconi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Francesca Coati

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Matteo Valerio

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Alberto Massocco

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

Maria C Pegoraro

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

publication date

26 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

204-213

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23887295 AND SRC:MED&resulttype=core&format=json

Triple-negative breast cancer: disease entity or title of convenience?

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Triple negative breast cancers: clinical and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Pathological definition of triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Most basal-like breast carcinomas demonstrate the same Rb-/p16 immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Tailoring to RB: tumour suppressor status and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

RB in breast cancer: at the crossroads of tumorigenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor‐negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Retinoblastoma protein: a central processing unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

7 January 2021

Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

7 January 2021

Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

7 January 2021

P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.137

7 January 2021